Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Targeted kinase inhibitors have advanced cancer management but face acquired resistance.
• Resistance limits the long-term effectiveness of many anticancer drugs.
• Identifying strategies to overcome acquired resistance is crucial for improving patient outcomes.

Purpose of the Study:

• To develop a general strategy to overcome acquired resistance to targeted anticancer therapies.
• To investigate the role of drug-induced MEK cleavage in preventing resistance.
• To evaluate the efficacy of this strategy across diverse cancer types and driver mutations.

Main Methods:

• Drug-induced MEK cleavage via direct procaspase-3 activation.
• Combination therapy of MEK cleavage induction and targeted kinase inhibition.
• Testing the strategy in various tumor histologies (melanoma, lung cancer, leukemia) and driver mutations (BRAF, EGFR, ALK, BCR-ABL).

Main Results:

• Drug-induced MEK cleavage combined with targeted inhibition effectively overcomes acquired resistance.
• This strategy demonstrated efficacy across diverse cancer types and driver mutations.
• Caspase-3-mediated MEK degradation led to sustained pathway inhibition and delayed/eliminated resistance.

Conclusions:

• Drug-mediated MEK kinase cleavage is a generalizable therapeutic strategy to prevent resistance to targeted anticancer therapies.
• This approach offers a significant improvement over current combination therapies involving MEK inhibitors.
• The findings suggest a promising new avenue for enhancing the durability of targeted cancer treatments.